Biomm S.A. Logo

Biomm S.A.

BIOM3.SA

(0.2)
Stock Price

10,36 BRL

-30.67% ROA

-65.79% ROE

-4.85x PER

Market Cap.

737.273.747,00 BRL

131.77% DER

0% Yield

-68.72% NPM

Biomm S.A. Stock Analysis

Biomm S.A. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Biomm S.A. Fundamental Stock Analysis
# Analysis Rating
1 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

2 ROE

Negative ROE (-67.3%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

3 ROA

The stock's ROA (-30.67%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

4 PBV

The stock's elevated P/BV ratio (4.04x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

5 DER

The company has a high debt to equity ratio (132%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

The company's stock appears overvalued (-8) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Biomm S.A. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Biomm S.A. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Biomm S.A. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Biomm S.A. Revenue
Year Revenue Growth
2006 6.645.000
2007 1.995.000 -233.08%
2008 3.017.000 33.87%
2009 608.000 -396.22%
2010 877.000 30.67%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 103.000 100%
2018 1.566.000 93.42%
2019 8.944.000 82.49%
2020 58.668.000 84.75%
2021 107.090.000 45.22%
2022 104.954.000 -2.04%
2023 123.096.000 14.74%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Biomm S.A. Research and Development Expenses
Year Research and Development Expenses Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Biomm S.A. General and Administrative Expenses
Year General and Administrative Expenses Growth
2006 4.010.000
2007 4.737.000 15.35%
2008 5.991.000 20.93%
2009 3.844.000 -55.85%
2010 4.661.000 17.53%
2011 4.041.000 -15.34%
2012 7.739.000 47.78%
2013 10.087.000 23.28%
2014 15.795.000 36.14%
2015 20.251.000 22%
2016 27.420.000 26.15%
2017 31.237.000 12.22%
2018 32.604.000 4.19%
2019 45.020.000 27.58%
2020 33.862.000 -32.95%
2021 47.290.000 28.4%
2022 50.166.000 5.73%
2023 50.844.000 1.33%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Biomm S.A. EBITDA
Year EBITDA Growth
2006 254.000
2007 -4.971.000 105.11%
2008 -4.880.000 -1.86%
2009 -3.102.000 -57.32%
2010 -4.053.000 23.46%
2011 -4.123.000 1.7%
2012 -15.996.000 74.22%
2013 -5.087.000 -214.45%
2014 -10.659.000 52.28%
2015 350.000 3145.43%
2016 -43.601.000 100.8%
2017 -32.502.000 -34.15%
2018 -30.984.000 -4.9%
2019 -40.438.000 23.38%
2020 -48.651.000 16.88%
2021 -53.760.000 9.5%
2022 -66.662.000 19.35%
2023 -54.900.000 -21.42%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Biomm S.A. Gross Profit
Year Gross Profit Growth
2006 4.350.000
2007 465.000 -835.48%
2008 928.000 49.89%
2009 390.000 -137.95%
2010 441.000 11.56%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 36.000 100%
2018 245.000 85.31%
2019 521.000 52.98%
2020 13.936.000 96.26%
2021 26.934.000 48.26%
2022 15.996.000 -68.38%
2023 19.920.000 19.7%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Biomm S.A. Net Profit
Year Net Profit Growth
2006 6.000
2007 -5.318.000 100.11%
2008 -7.412.000 28.25%
2009 -7.016.000 -5.64%
2010 -4.273.000 -64.19%
2011 -4.675.000 8.6%
2012 -14.140.000 66.94%
2013 -10.059.000 -40.57%
2014 -12.713.000 20.88%
2015 8.282.000 253.5%
2016 -45.608.000 118.16%
2017 -38.128.000 -19.62%
2018 -42.562.000 10.42%
2019 -55.812.000 23.74%
2020 -70.767.000 21.13%
2021 -80.261.000 11.83%
2022 -92.559.000 13.29%
2023 -80.816.000 -14.53%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Biomm S.A. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2006 0
2007 -1 0%
2008 -1 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 -1 0%
2013 -1 0%
2014 0 0%
2015 0 0%
2016 -1 100%
2017 -1 0%
2018 -1 0%
2019 -1 0%
2020 -1 0%
2021 -1 0%
2022 -1 0%
2023 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Biomm S.A. Free Cashflow
Year Free Cashflow Growth
2008 -5.715.000
2009 -5.577.000 -2.47%
2010 -5.141.000 -8.48%
2011 -2.814.000 -82.69%
2012 -8.018.000 64.9%
2013 -42.288.000 81.04%
2014 -112.048.000 62.26%
2015 -48.213.000 -132.4%
2016 -101.433.000 52.47%
2017 -60.212.000 -68.46%
2018 -45.260.000 -33.04%
2019 -88.202.000 48.69%
2020 -101.501.000 13.1%
2021 -101.226.000 -0.27%
2022 -68.438.000 -47.91%
2023 -11.878.000 -476.17%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Biomm S.A. Operating Cashflow
Year Operating Cashflow Growth
2008 -5.715.000
2009 -5.310.000 -7.63%
2010 -4.640.000 -14.44%
2011 -1.784.000 -160.09%
2012 -7.103.000 74.88%
2013 -10.508.000 32.4%
2014 -19.784.000 46.89%
2015 -13.899.000 -42.34%
2016 -38.281.000 63.69%
2017 -54.405.000 29.64%
2018 -44.115.000 -23.33%
2019 -80.852.000 45.44%
2020 -96.874.000 16.54%
2021 -93.784.000 -3.29%
2022 -62.999.000 -48.87%
2023 -11.470.000 -449.25%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Biomm S.A. Capital Expenditure
Year Capital Expenditure Growth
2008 0
2009 267.000 100%
2010 501.000 46.71%
2011 1.030.000 51.36%
2012 915.000 -12.57%
2013 31.780.000 97.12%
2014 92.264.000 65.56%
2015 34.314.000 -168.88%
2016 63.152.000 45.66%
2017 5.807.000 -987.52%
2018 1.145.000 -407.16%
2019 7.350.000 84.42%
2020 4.627.000 -58.85%
2021 7.442.000 37.83%
2022 5.439.000 -36.83%
2023 408.000 -1233.09%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Biomm S.A. Equity
Year Equity Growth
2006 3.089.000
2007 -2.229.000 238.58%
2008 -12.216.000 81.75%
2009 4.968.000 345.89%
2010 -4.061.000 222.33%
2011 -8.758.000 53.63%
2012 -21.995.000 60.18%
2013 108.936.000 120.19%
2014 107.101.000 -1.71%
2015 115.128.000 6.97%
2016 65.929.000 -74.62%
2017 59.301.000 -11.18%
2018 106.089.000 44.1%
2019 153.557.000 30.91%
2020 191.479.000 19.8%
2021 111.586.000 -71.6%
2022 159.109.000 29.87%
2023 120.928.000 -31.57%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Biomm S.A. Assets
Year Assets Growth
2006 11.157.000
2007 9.707.000 -14.94%
2008 12.170.000 20.24%
2009 15.639.000 22.18%
2010 4.907.000 -218.71%
2011 12.550.000 60.9%
2012 8.328.000 -50.7%
2013 138.078.000 93.97%
2014 179.564.000 23.1%
2015 229.673.000 21.82%
2016 237.385.000 3.25%
2017 262.387.000 9.53%
2018 305.683.000 14.16%
2019 388.771.000 21.37%
2020 434.970.000 10.62%
2021 369.831.000 -17.61%
2022 405.093.000 8.7%
2023 342.295.000 -18.35%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Biomm S.A. Liabilities
Year Liabilities Growth
2006 8.068.000
2007 11.936.000 32.41%
2008 24.386.000 51.05%
2009 10.671.000 -128.53%
2010 8.968.000 -18.99%
2011 21.308.000 57.91%
2012 30.323.000 29.73%
2013 29.142.000 -4.05%
2014 72.463.000 59.78%
2015 114.545.000 36.74%
2016 171.456.000 33.19%
2017 203.086.000 15.57%
2018 199.594.000 -1.75%
2019 235.214.000 15.14%
2020 243.491.000 3.4%
2021 258.245.000 5.71%
2022 245.984.000 -4.98%
2023 221.367.000 -11.12%

Biomm S.A. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.5
Net Income per Share
-1.12
Price to Earning Ratio
-4.85x
Price To Sales Ratio
6.04x
POCF Ratio
-5.5
PFCF Ratio
-8.55
Price to Book Ratio
3.66
EV to Sales
7.14
EV Over EBITDA
-14.52
EV to Operating CashFlow
-10.84
EV to FreeCashFlow
-10.11
Earnings Yield
-0.21
FreeCashFlow Yield
-0.12
Market Cap
0,74 Bil.
Enterprise Value
0,87 Bil.
Graham Number
6.11
Graham NetNet
-1.6

Income Statement Metrics

Net Income per Share
-1.12
Income Quality
0.94
ROE
-0.67
Return On Assets
-0.25
Return On Capital Employed
-0.27
Net Income per EBT
1.04
EBT Per Ebit
1.2
Ebit per Revenue
-0.55
Effective Tax Rate
-0.04

Margins

Sales, General, & Administrative to Revenue
0.4
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.16
Operating Profit Margin
-0.55
Pretax Profit Margin
-0.66
Net Profit Margin
-0.69

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.99
Free CashFlow per Share
-1.06
Capex to Operating CashFlow
0.07
Capex to Revenue
-0.05
Capex to Depreciation
-0.49
Return on Invested Capital
-0.28
Return on Tangible Assets
-0.31
Days Sales Outstanding
185.7
Days Payables Outstanding
74.07
Days of Inventory on Hand
128.85
Receivables Turnover
1.97
Payables Turnover
4.93
Inventory Turnover
2.83
Capex per Share
-0.07

Balance Sheet

Cash per Share
0,32
Book Value per Share
1,48
Tangible Book Value per Share
0.94
Shareholders Equity per Share
1.48
Interest Debt per Share
2.11
Debt to Equity
1.32
Debt to Assets
0.47
Net Debt to EBITDA
-2.25
Current Ratio
1.59
Tangible Asset Value
0,08 Bil.
Net Current Asset Value
-0,10 Bil.
Invested Capital
1.32
Working Capital
0,05 Bil.
Intangibles to Total Assets
0.13
Average Receivables
0,05 Bil.
Average Payables
0,02 Bil.
Average Inventory
42244000
Debt to Market Cap
0.22

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Biomm S.A. Dividends
Year Dividends Growth

Biomm S.A. Profile

About Biomm S.A.

Biomm S.A. operates as a biotechnology company in Brazil. It offers AFREZZA, a human insulin inhalation powder; CONFORT CARE, a moisturizing foot cream; GLARGILIN, a glargine insulin; and HERZUMA, a trastuzumab. Biomm S.A. was founded in 2001 and is based in São Paulo, Brazil.

CEO
Mr. Heraldo Carvalho Marchezin
Employee
127
Address
Rua dos Pinheiros, 610
São Paulo, 05422-001

Biomm S.A. Executives & BODs

Biomm S.A. Executives & BODs
# Name Age
1 Renato Arroyo Barbeiro
Financial Director, IR & Member of Executive Board
70
2 Mr. Heraldo Carvalho Marchezini
Chief Executive Officer & Member of The Executive Board
70
3 Mr. Francisco Carlos Marques de Freitas
Chief Operating Officer & Member of The Executive Board
70
4 Mr. Francisco Rafael Costa Jr.
Commercial Director & Member of Executive Board
70

Biomm S.A. Competitors